Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Pharmacoecon Outcomes Res. 2003 Apr;3(2):147-58. doi: 10.1586/14737167.3.2.147.

Economic evaluations of neuraminidase inhibitors to control influenza.

Author information

Institut National de la Santé Et de la Recherche Médicale, INSERM Unit 444, Hôpital Saint-Antoine, 27 rue de Chaligny, 75012 Paris, France.


Up to 10% of individuals present influenza-like illness each year. Neuraminidase inhibitors significantly reduce the median duration of influenza symptoms by 1.38 days and median time to return to normal activities by 0.9 days in adults. This review presents the economic evaluations of neuraminidase inhibitors in adults. The choice of key parameter estimates in cost-effectiveness and cost-benefit analysis is sensitive to the perspective of analysis: healthcare payer or societal, including productivity gains. This review discusses, among other key parameters, the proportion of influenza-like illness due to the influenza virus (targeted by neuraminidase inhibitors and influenza vaccine), and the measure of health benefits by either quality-adjusted life years gained or willingness-to-pay for a day of symptoms averted. Overall, neuraminidase inhibitors are worth their costs and do not challenge annual influenza vaccination but should be seen as a complementary option to reduce the burden of influenza.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center